A Phase 1 interventional study of Tasimelteon Oral Capsule and Tasimelteon Oral Suspension in Healthy, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.
Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single center, two-period, randomized study to evaluate the bioequivalence of a single dose of tasimelteon capsule formulation relative to a single dose of liquid suspension formation in healthy volunteers.
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tasimelteon liquid suspension formulation then tasimelteon capsule formulation
Drug: Tasimelteon Oral Capsule · Drug: Tasimelteon Oral Suspension
tasimelteon capsule formulation then tasimelteon liquid suspension formulation
Drug: Tasimelteon Oral Capsule · Drug: Tasimelteon Oral Suspension
No additional information
No additional information
Bioequivalence between tasimelteon capsule formulation relative to tasimelteon liquid suspension formulation
as measured by plasma concentrations
Time frame: 8 hours
Assessment of Safety and Tolerability of the liquid suspension and capsule formulation of tasimelteon
as measured by incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Jun 2022, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon